PA8575401A1 - Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso - Google Patents

Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso

Info

Publication number
PA8575401A1
PA8575401A1 PA20038575401A PA8575401A PA8575401A1 PA 8575401 A1 PA8575401 A1 PA 8575401A1 PA 20038575401 A PA20038575401 A PA 20038575401A PA 8575401 A PA8575401 A PA 8575401A PA 8575401 A1 PA8575401 A1 PA 8575401A1
Authority
PA
Panama
Prior art keywords
methods
pharmaceutical compositions
tienopiridins
heteroarilamide
benzocondensed
Prior art date
Application number
PA20038575401A
Other languages
English (en)
Spanish (es)
Inventor
Michael Raymond Collins
Stephan James Cripps
Judith Gail Deal
William Henry Romines Iii
Robert Steven Kania
Mingying He
Jihong Lou
Ru Zhou
Cynthia Louise Palmer
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8575401A1 publication Critical patent/PA8575401A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
PA20038575401A 2002-06-14 2003-06-12 Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso PA8575401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38911002P 2002-06-14 2002-06-14

Publications (1)

Publication Number Publication Date
PA8575401A1 true PA8575401A1 (es) 2004-05-07

Family

ID=29736588

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038575401A PA8575401A1 (es) 2002-06-14 2003-06-12 Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso

Country Status (36)

Country Link
US (3) US6869962B2 (enExample)
EP (1) EP1515975B1 (enExample)
JP (1) JP2005534669A (enExample)
KR (2) KR100671632B1 (enExample)
CN (1) CN1671714A (enExample)
AP (1) AP2004003184A0 (enExample)
AR (1) AR039673A1 (enExample)
AT (1) ATE373665T1 (enExample)
AU (1) AU2003233134A1 (enExample)
BR (1) BR0311806A (enExample)
CA (1) CA2489466A1 (enExample)
CO (1) CO5631447A2 (enExample)
DE (1) DE60316440T2 (enExample)
EA (1) EA008255B1 (enExample)
EC (1) ECSP045483A (enExample)
ES (1) ES2290460T3 (enExample)
GE (1) GEP20074033B (enExample)
GT (1) GT200300129A (enExample)
HN (1) HN2003000182A (enExample)
HR (1) HRP20041173A2 (enExample)
IL (1) IL165591A0 (enExample)
IS (1) IS7552A (enExample)
MA (1) MA27596A1 (enExample)
MX (1) MXPA04011637A (enExample)
NO (1) NO20045103L (enExample)
NZ (1) NZ537140A (enExample)
OA (1) OA12865A (enExample)
PA (1) PA8575401A1 (enExample)
PE (1) PE20050123A1 (enExample)
PL (1) PL374542A1 (enExample)
RS (1) RS107504A (enExample)
TN (1) TNSN04246A1 (enExample)
TW (1) TW200404070A (enExample)
UA (1) UA77303C2 (enExample)
WO (1) WO2003106462A1 (enExample)
ZA (1) ZA200409862B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032872A1 (fr) * 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
EP1549638B1 (en) * 2002-10-03 2007-10-03 F. Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
ATE508747T1 (de) * 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
EP1683785B1 (en) * 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
JP2007518823A (ja) * 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
US8772269B2 (en) * 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030941A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery
WO2006117666A2 (en) * 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
CN101277720A (zh) * 2005-09-01 2008-10-01 卫材R&D管理有限公司 崩解性被改善的药物组合物的制备方法
WO2007026221A2 (en) * 2005-09-02 2007-03-08 Pfizer Inc. Improved methods for preparing benzofused heteroaryl amide derivatives of thienopyridines
WO2007052849A1 (ja) * 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
AR059246A1 (es) * 2006-01-30 2008-03-19 Array Biopharma Inc Compuestos heterobiciclicos de tiofeno y metodos de uso
EP1984334B1 (en) * 2006-02-15 2014-04-09 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
CA2652442C (en) * 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
US20090203693A1 (en) * 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
KR101472600B1 (ko) * 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
CN101600694A (zh) * 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN105777776B (zh) * 2007-08-29 2021-06-08 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂
ES2593279T3 (es) * 2007-08-29 2016-12-07 Methylgene Inc. Procesos e intermedios para preparar inhibidores de cinasa heterocíclicos condensados
WO2009060945A1 (ja) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. 血管新生阻害物質と抗腫瘍性白金錯体との併用
JP5399926B2 (ja) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
US8815892B2 (en) 2008-03-25 2014-08-26 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
EP2105164B1 (en) * 2008-03-25 2011-01-12 Affectis Pharmaceuticals AG Novel P2X7R antagonists and their use
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
IN2012DN02493A (enExample) * 2009-09-03 2015-08-28 Allergan Inc
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
ES2979168T3 (es) 2010-07-23 2024-09-24 Univ Boston Inhibidores anti-DEspR como productos terapéuticos para inhibición de angiogénesis patológica e invasividad de células tumorales y para imagenología molecular y administración dirigida
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
IL302218B2 (en) 2014-08-28 2024-10-01 Eisai R&D Man Co Ltd Methods for manufacturing high-purity lenvatinib and its derivatives
CN104628686A (zh) * 2015-01-27 2015-05-20 南通恒盛精细化工有限公司 一种带酰胺侧链的苯并呋喃制备工艺
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
RU2750539C2 (ru) 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция для лечения опухоли
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN109053524A (zh) * 2018-09-11 2018-12-21 山东谛爱生物技术有限公司 一种N-Boc-3-羟基氮杂环丁烷的制备方法
US20220056043A1 (en) * 2019-02-19 2022-02-24 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof
WO2021057256A1 (zh) * 2019-09-29 2021-04-01 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559616A (en) * 1984-10-03 1985-12-17 Quadri Corporation Fast, non-volatile semiconductor/bubble memory with temperature-compensated magnetic bias field
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
FI941572L (fi) * 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE419355T1 (de) * 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
JP2890267B2 (ja) 1994-02-23 1999-05-10 ファイザー インク． ４−ヘテロサイクリル−置換キナゾリン誘導体、その調製法および抗癌剤としてのその使用法
JPH10509708A (ja) 1994-11-10 1998-09-22 コア セラピューティクス，インコーポレイティド プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
CA2218503C (en) * 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP3290666B2 (ja) 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0780386B1 (en) 1995-12-20 2002-10-02 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
CA2259222A1 (en) * 1996-06-27 1997-12-31 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
DE69718472T2 (de) 1996-07-13 2003-11-06 Glaxo Group Ltd., Greenford Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
KR20000067904A (ko) 1996-07-18 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 매트릭스 메탈로프로테아제의 포스피네이트계 억제제
BR9711223A (pt) 1996-08-23 1999-08-17 Pfizer Derivados de cido arilsulfonilamino-hidrox mico
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
BR9713552A (pt) 1996-11-27 2000-01-25 Pfizer Derivados de pirimidina bicìclicos condensados
EP0950059B1 (en) 1997-01-06 2004-08-04 Pfizer Inc. Cyclic sulfone derivatives
IL131042A0 (en) 1997-02-03 2001-01-28 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives
BR9807824A (pt) 1997-02-07 2000-03-08 Pfizer Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
KR20000070923A (ko) 1997-02-11 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐 하이드록삼산 유도체
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
US5835420A (en) 1997-06-27 1998-11-10 Aplus Flash Technology, Inc. Node-precise voltage regulation for a MOS memory system
AU8816298A (en) 1997-08-22 1999-03-16 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
US6061742A (en) * 1997-10-10 2000-05-09 Nortel Networks Corporation Computer network adaptor
CA2306082A1 (en) 1997-10-27 1999-05-06 Agouron Pharmaceuticals, Inc. Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors
HUP0100287A3 (en) * 1997-11-11 2003-04-28 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US6269027B1 (en) * 1998-04-14 2001-07-31 Honeywell, Inc. Non-volatile storage latch
CA2314156C (en) 1998-05-29 2010-05-25 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
JP2002533404A (ja) 1998-12-23 2002-10-08 ジー・ディー・サール・アンド・カンパニー 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法
DE10015193A1 (de) * 2000-03-27 2001-10-25 Infineon Technologies Ag Hochintegrierte System-on-Chip-Systeme mit nichtflüchtigen Speichereinheiten
DE60106022T2 (de) * 2000-06-06 2006-03-09 Pfizer Products Inc., Groton Thiophenverbindungen zur verwendung als antikrebsmittel
US6995171B2 (en) * 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
JP2005527511A (ja) 2002-03-01 2005-09-15 ファイザー インコーポレイテッド 抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法

Also Published As

Publication number Publication date
JP2005534669A (ja) 2005-11-17
IL165591A0 (en) 2006-01-15
GEP20074033B (en) 2007-02-12
GT200300129A (es) 2004-03-17
US20060079548A1 (en) 2006-04-13
IS7552A (is) 2004-11-25
ATE373665T1 (de) 2007-10-15
UA77303C2 (en) 2006-11-15
KR100671632B1 (ko) 2007-02-28
US7045528B2 (en) 2006-05-16
MXPA04011637A (es) 2005-03-07
HRP20041173A2 (en) 2005-06-30
AP2004003184A0 (en) 2004-12-31
DE60316440T2 (de) 2008-01-24
PL374542A1 (en) 2005-10-31
TW200404070A (en) 2004-03-16
ES2290460T3 (es) 2008-02-16
PE20050123A1 (es) 2005-03-22
EA008255B1 (ru) 2007-04-27
HN2003000182A (es) 2004-07-27
OA12865A (en) 2006-09-15
ECSP045483A (es) 2005-01-28
NZ537140A (en) 2006-10-27
EP1515975A1 (en) 2005-03-23
US20040009965A1 (en) 2004-01-15
WO2003106462A1 (en) 2003-12-24
AU2003233134A1 (en) 2003-12-31
KR20060110011A (ko) 2006-10-23
KR100714545B1 (ko) 2007-05-07
EA200500018A1 (ru) 2005-06-30
MA27596A1 (fr) 2005-11-01
US6869962B2 (en) 2005-03-22
EP1515975B1 (en) 2007-09-19
KR20050008821A (ko) 2005-01-21
CO5631447A2 (es) 2006-04-28
CN1671714A (zh) 2005-09-21
TNSN04246A1 (fr) 2007-03-12
US20040186126A1 (en) 2004-09-23
CA2489466A1 (en) 2003-12-24
ZA200409862B (en) 2006-05-31
AR039673A1 (es) 2005-03-09
DE60316440D1 (de) 2007-10-31
RS107504A (sr) 2006-10-27
NO20045103L (no) 2005-02-17
BR0311806A (pt) 2005-03-29

Similar Documents

Publication Publication Date Title
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
PA8518701A1 (es) Derivados de tiofeno utiles como agentes anticancerosos
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
UY28040A1 (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos.
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
PA8609701A1 (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
SE0402762D0 (sv) Indazole sulphonamide derivatives
SE0301446D0 (sv) New Compounds
SV2004001548A (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
PA8576001A1 (es) "difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion , medicamentos que comprenden estos compuestos y su uso".
UY28377A1 (es) Agentes terapeuticos
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos